| 1.5 0.03 (2.04%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.86 | 1-year : | 2.18 |
| Resists | First : | 1.6 | Second : | 1.86 |
| Pivot price | 1.46  |
|||
| Supports | First : | 1.21 | Second : | 0.97 |
| MAs | MA(5) : | 1.47 |
MA(20) : | 1.4 |
| MA(100) : | 0.81 |
MA(250) : | 0.59 |
|
| MACD | MACD : | 0.1  |
Signal : | 0.1 |
| %K %D | K(14,3) : | 70.3 |
D(3) : | 69.8 |
| RSI | RSI(14): 61.9 |
|||
| 52-week | High : | 1.6 | Low : | 0.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CATX ] has closed below upper band by 34.3%. Bollinger Bands are 20.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.5 - 1.51 | 1.51 - 1.51 |
| Low: | 1.35 - 1.35 | 1.35 - 1.36 |
| Close: | 1.49 - 1.5 | 1.5 - 1.51 |
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Tue, 16 Apr 2024
Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Down 7.2% - MarketBeat
Mon, 15 Apr 2024
Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 3.7% - MarketBeat
Wed, 10 Apr 2024
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Sees Significant Growth in Short Interest - MarketBeat
Sat, 30 Mar 2024
Perspective Therapeutics Inc (CATX) Reports Fiscal Year 2023 Financial Results - Yahoo Finance
Thu, 28 Mar 2024
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results - Yahoo Finance
Tue, 05 Mar 2024
Perspective Therapeutics acquires New Jersey facility By Investing.com - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 281 (M) |
| Shares Float | 203 (M) |
| Held by Insiders | 22.3 (%) |
| Held by Institutions | 15 (%) |
| Shares Short | 1,840 (K) |
| Shares Short P.Month | 2,050 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | 0 % |
| Operating Margin | -482.2 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 27.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -0.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -25 |
| PEG Ratio | 0 |
| Price to Book value | 4.28 |
| Price to Sales | 66.69 |
| Price to Cash Flow | -12.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|